10-25% weight of benzylbenzoate in a ricinoleate vehicle per volume of formulation
and a sufficient amount of a ricinoleate vehicle so as to prepare
a formulation of at least 45 mgml-1 of fulvestrant.
24. Use of fulvestrant in the preparation of a pharmaceutical formulation for the treatment of breast cancer by intra-muscular administration, wherein the pharmaceutical formulation comprises
fulvestrant, 17-23% weight of a pharmaceutically-acceptable
alcohol per volume of formulation, 12-18%